Vivet Therapeutics is a Paris-based clinical-stage biotech developing novel and long-lasting gene therapies for rare inherited metabolic disorders. Its gene therapy platform uses recombinant adeno-associated viruses (rAAVs) as vectors and has initiated two clinical programs and four pre-clinical assets. The company’s most advanced therapy is VTX-801, a gene therapy for Wilson’s Disease, with key clinical read-outs expected by the end of 2024. A second program, VTX-806, is in development as a potential treatment option for CTX patients. Vivet received EUR 4.9M in financing from the French Government under the France Health Innovation Plan 2030 operated by Bpifrance to further develop VTX-806. The company is backed by international life-science investors including Novartis Venture Fund, Roche Venture Fund, HealthCap, Pfizer, Columbus Venture Partners, Ysios Capital, Kurma Partners and Eurazeo. Vivet Therapeutics is a biotechnology company developing novel gene therapies for rare, inherited metabolic liver diseases, with a lead program targeting Wilson disease. Its lead candidate, VTX-801, is an investigational AAV-based gene therapy that has received Orphan Drug Designation from both the FDA and the European Commission. Vivet is also advancing liver-directed programs for progressive familial intrahepatic cholestasis (PFIC) and citrullinemia. The company builds a diversified AAV technology pipeline through partnerships and exclusive licenses from the Fundación para la Investigación Médica Aplicada (FIMA) at CIMA/University of Navarra. Vivet is led by Co‑Founder & CEO Jean-Phillippe Combal and Co‑Founder & CSO Gloria Gonzalez-Aseguinolaza. Financially, Pfizer made a strategic investment of approximately €45m for a 15% equity stake and secured an exclusive option to acquire the company, potentially bringing total consideration to as much as €560m contingent on clinical, regulatory, and commercial milestones. Vivet Therapeutics is a Paris-based biotech focused on developing novel gene therapies for rare, inherited metabolic diseases. Its lead program, VTX801, is an investigational gene therapy for Wilson disease. The company is building a diversified pipeline targeting Wilson disease, PFIC2, PFIC3 and citrullinemia type I. Vivet's technology relies on novel AAV approaches developed through partnerships and exclusive licenses from the Fundación para la Investigación Médica Aplicada (FIMA) at CIMA (University of Navarra) and the Massachusetts Eye and Ear of Harvard Medical School. Founded in 2016 by Jens Kurth, Gloria Gonzalez Aseguinolaza and Jean Philippe Combal, the company also has a wholly owned subsidiary in Spain. Vivet raised €37.5m in a Series A to advance its pipeline.

Total raised

$97M

Funding rounds

3

Latest round

Equity

Latest activity

Feb 2024